SymbolACET
NameADICET BIO, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address200 CLARENDON STREET,FLOOR 6, BOSTON, Massachusetts, 02116, United States
Telephone+1 650 503-9095
Fax
Email
Websitehttps://www.adicetbio.com
IncorporationUNDEFINED
Incorporated On
Employees
Fiscal Year
Public Since
ExchangesNASDAQ
Auditor
Audit StatusNOT PROVIDED
Reporting Status
CIK0001720580
Description

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.

Additional info from NASDAQ:
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.

2026-09-02 20:00

Adicet Bio to Participate in Fireside Chat at H.C. Wainwright 28th Annual Global Investment Conference

Read more
2026-09-01 11:02

(30% Negative) ADICET BIO, INC. (ACET) Announces Delay in development Trials for ADI-212 in mCRPC Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Read more
2026-09-01 11:00

Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate Update

Read more
2026-08-31 21:39

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Read more
2026-08-27 20:00

Adicet Bio Announces FDA Clearance of IND Application for ADI-212

Read more
2026-08-07 20:01

Klickstein Lloyd 🟢 acquired 18.3K shares (1 derivative) of Adicet Bio, Inc. (ACET) at $9.16 Transaction Date: Aug 05, 2026 | Filing ID: 000003

Read more
2026-08-05 20:15

Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates

Read more
2026-07-21 20:00

Adicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth Conference

Read more
2026-06-23 22:51

Schor Chen 🟢 acquired 55.0K shares (1 derivative) of Adicet Bio, Inc. (ACET) at $8.10 Transaction Date: Jun 19, 2026 | Filing ID: 000007

Read more
2026-06-23 22:49

Aftab Blake 🟢 acquired 55.0K shares (1 derivative) of Adicet Bio, Inc. (ACET) at $8.10 Transaction Date: Jun 19, 2026 | Filing ID: 000004

Read more